ANGLE plc
AGL.L
London Stock Exchange0.92
GBp
-0.05
- -
ANGLE plc
AGL.L
(London Stock Exchange)
Recent
price
0.92
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ANGLE plc (AIM: AGL.L), now operating as CelLBxHealth plc following a name change effective October 2025, is a world-leading liquid biopsy company that develops and commercializes innovative circulating tumor cell (CTC) diagnostic solutions for research, drug development, and clinical oncology using simple blood samples. The company's core products and services include the patented and FDA-cleared Parsortix PC1 system and associated single-use cell separation cassettes for the capture and harvest of intact CTCs and CTC clusters from whole blood; downstream analysis capabilities encompassing whole-cell imaging, proteomic profiling, full genomic and transcriptomic molecular analysis, and a proprietary DNA dual analysis workflow using Illumina Next Generation Sequencing (NGS) panels for simultaneous CTC-DNA and ctDNA assessment from a single sample; GCP-compliant laboratory services offered globally through facilities in the UK and US, featuring custom assay development, clinical trial testing for pharmaceutical clients, and validated assays such as HER2, AR, and DDR for oncology applications. These offerings target biopharmaceutical companies, clinical researchers, healthcare providers, and medtech partners, with a sharpened strategic focus on CTC intelligence in proteomics and genomics markets to complement ctDNA solutions. Founded in 1994 and headquartered at 10 Nugent Road, Surrey Research Park, Guildford, England, the company maintains operations in the United Kingdom, United States, Canada, Europe, and internationally. ANGLE plc serves the biotechnology and medical diagnostics industry, emphasizing precision oncology through non-invasive, repeatable monitoring of cancer progression, therapeutic response, and recurrence in applications such as metastatic breast cancer. Recent major developments include the successful completion of contracts with large pharmaceutical companies AstraZeneca, Eisai, and biopharma firm Immatics across multiple clinical trials, including Phase 3 studies in melanoma, alongside ongoing discussions for new projects and the commercialization of validated assays like HER2 for tracking patient status changes. Post-period highlights feature a strategic collaboration with Myriad Genetics to adapt its FDA-approved tissue-based companion diagnostic assay to CTC-based samples via Parsortix, potentially enabling substantial clinical revenues; a new agreement with US biotech Recursion Pharmaceuticals, marking the fourth such pharma deal in 2024; development of the Illumina NGS-integrated workflow; and eleven new peer-reviewed publications, including ground-breaking research in Nature Medicine supporting a spin-out for anti-metastasis drugs. In tandem, the company announced a revised strategy under executive chair Jan Groen, emphasizing cost control, accelerated commercialization, and a pivot to high-value CTC-based precision diagnostics, with a planned fundraising ahead of its Q1 2026 cash runway.